Use of wireless technology allows the information from the implanted device to automatically update to a device such as a cell phone or other wireless unit designed to work with the device..physicians and hospitals can get patient updates on vitals and also more importantly, the status of the device as well....BD
MINNEAPOLIS & SAN FRANCISCO--(HSMN NewsFeed)--Leading into Heart
Rhythm 2008, the pre-eminent worldwide gathering of cardiologists specializing in electrophysiology, Medtronic, Inc. (NYSE: MDT ) today announced U.S. Food and Drug Administration (FDA) approval of the first wave of cardiac rhythm disease management therapies under the new Vision 3D™ portfolio, which will co
mprise a full line of implantable cardioverter-defibrillators (ICDs), cardiac resynchronization therapy-defibrillators (CRT-Ds), pacemakers and cardiac resynchronization therapy-pacemakers (CRT-Ps) to address the needs of patients with arrhythmias, heart failure and those at risk of sudden cardiac arrest (SCA). The portfolio’s first ICD and CRT-D devices will be commercially available in the coming months.
Complete automaticity provides physicians flexibility during in-office device checks and may also reduce battery drain.
“For the first time, we have access to sophisticated defibrillators with complete automaticity to capture what’s happening in three chambers of the heart and adjust the device’s stimulation to the body’s physiologic needs,” said Anne Curtis, M.D., FHRS, FACC, FAHA, chief of the Division of Cardiology and director of Cardiovascular Services at the University of South Florida.
0 comments :
Post a Comment